Vext Science AI Stock Analysis
Want to see TSE:VEXT full AI Analyst Report?
Vext Science (VEXT) AI Stock Analysis
Vext Science
(CNQX:VEXT)
The overall score of 48 reflects a high-risk, turnaround situation. The most significant factor is the company's severely deteriorated financial performance, with collapsing margins and negative free cash flow. This is partially offset by a more constructive earnings call, which highlighted a credible strategic pivot to Ohio, significant margin recovery, and balance sheet repair efforts. Technical weakness and a negative P/E ratio further weigh on the score, indicating the market has yet to price in a successful turnaround.
Vext Science (VEXT) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 32.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 68.83K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 0.44
- Revenue Growth
- 9.88%
- EPS Growth
- 0.18%
- Country
- Canada
- Employees
- 173
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Vext Science Business Overview & Revenue Model
Company Description
Vext Science, Inc. operates as a comprehensive enterprise within the United States' cannabis sector, encompassing agricultural technology, various services, and property management. The company is actively involved in cultivating, extracting, manufac...
Vext Science Earnings Call Summary
The call emphasized meaningful operational and margin improvements driven by Ohio execution and higher cultivation yields, alongside successful financing and balance sheet progress. These positives were balanced against a lower top line (driven by a planned Arizona cultivation wind-down), ongoing market weakness in Arizona, a significant uncertain tax liability, and modest reported operating cash flow due to deliberate inventory and payable timing. Management communicated a clear strategy to redeploy capital from Arizona to Ohio and to pay down debt, and they reported concrete near-term actions and improving trends.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided to improved H2 performance as Arizona’s repositioning to a capital‑light retail/third‑party sourcing model completes, Ohio inventory converts to cash, Fairfield and the broader Ohio footprint scale, and capital is directed to strengthening the balance sheet, paying down debt, and funding Ohio growth; Q2 metrics cited as context include revenue of $12.1M (≈‑10% YoY, flat QoQ) with wholesale revenue down to $1.4M from $2.6M, gross profit $6.7M (vs $4.9M a year ago) and gross margin 55% (36% YoY; 44% before fair‑value adj.), adjusted EBITDA $3.4M (+22% QoQ from a corrected Q1 $2.8M) with a 28% adjusted EBITDA margin (vs 23%), net loss narrowed to $0.3M (vs $1.5M), cash from operations $1.2M (~10% cash‑flow margin) despite a deliberate $2M Ohio inventory build (expected to convert through H2; Ohio wholesale set a preliminary monthly record in July), cultivation yields now >100 g/plant (up ~68% over 2.5 years), Eloy property reclassified held‑for‑sale at $7.8M with proceeds earmarked to pay secured debt, cash ~$4.5M, net working capital improved from ‑$11.7M to ≈‑$0.9M (would be positive excluding an $11.7M uncertain tax position up from $8.1M), WPCU financing gross proceeds ≈$17M (used to refinance ~$10.5M WPCU debt, acquire Jackson, OH for $6M and fund expansion), and the East West Bank note maturity extended to Jan 2028.
Vext Science Financial Statement Overview
Summary
Financial performance is weak, driven by a severe collapse in profitability despite recent revenue growth. Gross margins have plummeted from 65.2% to 6.8% TTM, and the company has swung to a net loss. The balance sheet shows rising leverage with equity declining, and free cash flow has turned negative, indicating an unsustainable trajectory.
Income Statement
18Very NegativeBalance Sheet
42NeutralCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.74M | 52.27M | 36.00M | 34.81M | 35.41M | 37.24M |
| Gross Profit | 3.50M | 2.32M | 8.98M | 12.04M | 23.10M | 18.69M |
| EBITDA | 1.92M | 6.80M | -2.02M | 16.77M | 15.29M | 12.82M |
| Net Income | -11.60M | -18.31M | -22.44M | 4.40M | 10.92M | 4.99M |
Balance Sheet | ||||||
| Total Assets | 118.95M | 120.31M | 136.97M | 149.56M | 120.52M | 83.70M |
| Cash, Cash Equivalents and Short-Term Investments | 5.58M | 5.07M | 4.62M | 8.72M | 5.93M | 6.47M |
| Total Debt | 38.61M | 34.97M | 39.52M | 38.60M | 38.15M | 14.10M |
| Total Liabilities | 69.97M | 65.04M | 61.23M | 54.58M | 48.60M | 24.31M |
| Stockholders Equity | 48.98M | 55.27M | 75.74M | 94.98M | 71.92M | 59.39M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | 8.29M | 1.82M | 1.69M | -2.94M | -7.10M |
| Operating Cash Flow | 8.37M | 11.92M | 3.29M | 4.42M | 5.92M | 11.68M |
| Investing Cash Flow | -9.47M | -5.76M | -5.44M | -4.82M | -30.31M | -27.10M |
| Financing Cash Flow | 3.07M | -5.69M | -1.95M | 3.19M | 23.86M | 20.14M |
Vext Science Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.24, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.21 is Neutral, neither overbought nor oversold. The STOCH value of 27.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.
Vext Science Peers Comparison
Overall Rating
TSE:LABS57Neutral
TSE:VEXT48Neutral
TSE:LEEF45Neutral
TSE:AVCN42Neutral
TSE:CWEB42Neutral
TSE:PLTH39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | CAD 27.77M | -10.00 | -7.66% | ― | -9.31% | 66.84% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | CAD 44.59M | -1.59 | -31.34% | ― | 9.88% | 0.18% | |
| 45Neutral | CAD 67.22M | -1.73 | 206.83% | ― | ― | ― | |
| 42Neutral | CAD 13.44M | -4.54 | -65.40% | ― | -3.32% | -34.15% | |
| 42Neutral | CAD 66.59M | -0.89 | -139.31% | ― | -9.90% | -35.35% | |
| 39Underperform | CAD 40.24M | -1.11 | -59.17% | ― | -15.64% | 71.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:VEXT | Vext Science | 0.18 | -0.06 | -25.00% | |
| TSE:LEEF | Leef Brands Inc | 0.22 | -0.02 | -10.20% | |
| TSE:CWEB | Charlotte's Web Holdings (OTC) | 0.24 | 0.10 | 75.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | 0.00 | 0.00% | |
| TSE:PLTH | Planet 13 Holdings, Inc. | 0.12 | -0.10 | -44.19% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.14 | -59.18% |
Vext Science Corporate Events
Vext Reports Record Revenue and Stronger Operating Cash Flow
PositiveVext Science is a U.S.-based specialty retailer of regulated cannabis products, including flower and packaged goods, operating in Ohio and Arizona. Third-quarter revenue reached a record $14.9 million, up 23% sequentially and 18% year over year, whil...
Vext Science Reaches Ohio Dispensary Cap With Amelia License
PositiveVext Science has secured a provisional dual-use license for its eighth Ohio dispensary in Amelia, reaching the maximum number of stores allowed for a single operator in the state. The new location, paired with the recently opened Fairfield dispensary...
Vext Science Sets November 3 Date for Q3 2026 Results
NeutralVext Science, Inc., a U.S.-based specialty cannabis retailer operating in Ohio and Arizona, runs a largely vertically integrated model by owning its dispensaries, most underlying real estate, and supplying shelves from its own cultivation and manufac...
Vext Science Regains Full Sales Clearance for Vapen Products in Ohio
PositiveVext Science, Inc., a specialty cannabis retailer with vertically integrated operations in Ohio and Arizona, has built a model around owning its dispensaries and much of its real estate while supplying stores from both internal production and select...
Vext Reopens Ohio Dispensary and Eases 2026 Debt Maturity Burden
PositiveVext Science has reopened its Herbal Wellness Center dispensary in Jackson, Ohio after receiving authorization from the Ohio Division of Cannabis Control, restoring service to patients and customers in the area. The company emphasized its commitment...
Vext Science Shuts Jackson, Ohio Dispensary Amid Health-Event Probe
NegativeVext Science has voluntarily closed its Herbal Wellness Center dispensary in Jackson, Ohio at the request of the Ohio Division of Cannabis Control, which is investigating two serious adverse health events possibly involving products purchased at that...
Vext Science Boosts Q2 Profitability as Ohio Growth Offsets Arizona Exit
PositiveVext Science reported second-quarter 2026 revenue of $12.1 million, in line with the prior quarter, as growth in Ohio retail offset the planned wind-down of Arizona cultivation and wholesale operations. Adjusted EBITDA rose 22% sequentially to $3.4 m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
